SUBSCRIBE
SUBSCRIBE
News   FDA

Europe Approves Wyeth’s Enbrel for Psoriasis in Children

January 8, 2009 | 
1 min read

LONDON, Jan 8 (Reuters) - Wyeth’s established drug Enbrel has been approved by the European Commission as the first biologic treatment for children with severe plaque psoriasis, the U.S. company said on Thursday.

FDA Approvals Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
The court's decision cancels all agreements. Agreement between the parties to the dispute. Conflict resolution in court.
COVID-19
FDA Shoots Down Invivyd’s Bid to Expand EUA for COVID-19 Antibody
February 24, 2025
 · 
1 min read
 · 
Dan Samorodnitsky